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ABSTRACT
Intensitication ot treatment ot acute Iymphoblastic leukemia in children causes the increase ot side effects, in
this number diabetes mellitus. This disorder has a different character trom "real" diabetes, very complicated
etiology and most often - transitory duration. The diabetogenic activity is attributed tirst ot all to corticosteroids and
L-asparaginase. Early diagnosis and proper treatment (cessation ot diabetogenic drugs, a diet and insulin
therapy) make possible tast regression ot clinical and biochemical abnormalities and, what is the most important,
enables a continuation ot chemotherapy. We present 3 cases ot transitory diabetes mellitus in children with acute
Iymphoblastic leukemia.
INTRODUCTION
Intensitieation ot treatment ot aeute
Iymphoblastie leukemia (ALL) in ehildren
caused, that 65 - 75% ot patients have aetually
a real ehanee to be cured (Clavell et aL, 1986;
Matsuzaki et aL, 1996; Radwańska et aL,
1994; Silverman et aL, 1997). Untortunately,
this progress is assoeiated with increase ot
trequency ot various side effects, ineluding
diabetes mellitus and other hyperglyeemic
disorders.
Aeeording to Pastore et al. glyeaemia
disorders may oeeur in nearly 50% ot ehildren
with ALL at diagnosis, espeeially those over 10
years ot age and with diabetes in their tamily
history (pastore et aL, 1984). This is according
to decreased glucose recycling in blast cells,
leukemie intiltration in pancreas, failure ot
insulin synthesis and secretion and to physieal
and psychical stress (pastore et aL, 1984).
Among antileukemic drugs diabetogenie
activity is attributed to glyeocorticosteroids and
L-asparaginase, espeeially in combination
cases (Clavell et al., 1986; Matsuzaki et aL,
1996; Nagura et aL, 1994; Pastore et aL, 1984;
Skomra and Przybylska, 1992; Tatoń, 1985).
Hyperglycemia due to steroid administration is
related to the increased glueoneogenesis and
deereased tissue susceptibility to insuline and
thus to tissue glucose consumption (Kaiser,
1991; Tatoń, 1985). Clinically, steroid indueed
hyperglieemia is eharaeterized by normai or
nearly normai insulin seeretion, Jack ot
susceptibility to ketosis, aeidosis and
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glycosuria in hunger period and, lastly, to
regression or signiticant alleviation after
cessation of leukemia treatment (Tatoń, 1985).
Data coneerning the trequeney ot oecurrence
ot drug - indueed diabetes are divergent: they
range trom 0,2% among ALL patients (Skomra
and Przybylska, 1992) to 6-8% in generał
population (Tatoń, 1985). L-asparaginase as L-
asparagine degreding enzyme causes
decrease ot protein synthesis, in this number
insulin (Pastore et aL, 1984; Skomra and
Przybylska, 1992; Tatoń, 1985). Additional
importance has disturbance of insulin
receptors (Pastore et aL, 1984), abnormal
response of islet a and 13 cells to stimulating
impulses (Skomra and Przybylska, 1992) and
toxic tailure of the pancreas (Derwich et aL, in
print; Nagura et aL, 1994; Niemeyer et aL,
1991; Skomra and Przybylska, 1992; Tatoń,
1985) and other organs (Kurylak et aL, 1997).
Hyperglyeaemic states after L-asparaginase
application were observed in 1-14% (Skomra
and Przybylska, 1992) even in 23% of ALL
patients (pastore et al., 1984).
We present three eases ot transitory diabetes
mellitus after simultaneous application of
glycocortieoids and L-asparaginase in children
treated for ALL.
CASE DESCRIPTION
In all presented patients acute Iymphoblastie
leukemia ot common type was diagnosed.
Chemotherapy aceording to ALL-BFM 90
protocol, modified by Polish Pediatrie
LeukemialLymphoma Treatment Group tor low
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risk group (Radwańska et aL, 1996) was
applied in every case. In Table 1 the relevant
data are presented: time ot diabetes
appearance, clinical symptoms and laboratory
tindings. In all three cases we administered
diabetic diet and insulin treatment (Insulinum
Actrapid, Mixtard 30 HM and Humulin R) in
doses based on current glucose serum
concentration, tor 27, 10 and. 5 days
respectively. Additionally, in the tirst case,
during the treatment with glucocorticosteroids,
increase ot blood pressure occurred (RR -
140/100 mmHg) and temporary application ot a
hypotensive drug (nitedipine) was needed.
Moreover, elevated levels ot aminotransterase
(AIAt - 116 lU/I, AspAt - 178 lU/I, GGTP - 389
lU/I) and bilirubin (3,0 mg%) were found. In the
PCR HCV-RNA test, the presence ot hepatitis
C virus in the serum was detected. In the
second patient coexisting tungoid stomatitis,
leucopaenia (700 G/I), thrombocytopaenia (49
G/I), decrease ot the tibrinogen serum level
(70 mg%), and increase ot cholesterol (447
mg) and triglycerides (469 mg%) levels were
noted. The activity ot amylase and lipase in the
serum was normaI. We applied intensive
therapy using broad spectrum antibiotics
(ceftriaxone, ceturoxime, cetotaxime, netil-
micin, fluconazole), symptomatic drugs
(granulocyte colony stimulating tactor,
ranitidine), intusion tluids and - as a prophylaxis
- co-trimoxasole and colistin. Coexisting
hyperbilirubinemia (5,99 mg%) and hypertrans-
aminasemia (AIAt - 255 lU/I, AspAt - 47 lU/I) in
the third patient were treated simptomatically
(Hepa-Merz and intusion tluids). Next, after
achieving improvement ot the clinical state and
normalization ot glycaemia we continued
chemotherapy with application ot
corticosteroids and L-asparaginase, replacing
dexamethasone with prednisone in case 1 and
giving tour doses ot L-asparaginase in case 2
In case 3 treatment was performed without any
changes in the protocol.
At present all three children are alive in tirst
hematological and clinical remission, during
the maintenance therapy. Despite application
ot complete prednisone dose in reinductions
(Le. 40 mg/m2 ot body surface) repeated
hyperglycaemia was not observed.
DISCUSSION
Modern treatment ot ALL in children is more
effective, but not devoid ot undesirable effects,
which become more significant with therapy
hyperglycaemic state, most often connected
with the administration ot L-asparaginase and
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glucocorticosteroids (Clavell et aL, 1986;
Derwich et al.; Kaiser, 1991; Matsuzaki et aL,
1996; Nagura et aL, 1994; Pastore et aL, 1984;
Tatoń, 1985; Wang and Chu, 1993). In the
second ot our cases hyperglicaemia occured
during dexamethasone application according
to 1\ protocol, however in one case - already in
the initial phase, it appeared after 5 days ot
prednisone therapy. In none ot our patients
(independently ot their tamily history and ot
diagnostic tests) diabetes was detected. This
tact points at the effects ot the drugs and
excludes, as is known trom literature, the
hyperglycaemic effect ot leukemia itselt
(Pastore et aL, 1984). It seems that etiology ot
diabetes occuring in leukemia patients is very
complicated and covers every tactor
mentioned above. Pastore's et al.
investigations about lack ot signiticant
differences in glucose serum levels betore and
after L-asparaginase application, show the role
ot the accumulation ot drug doses, not only
direct toxicity (Pastore et aL, 1984). These
authors also suggest, that leukemic process
itselt plays a basic role in the disclosure ot
diabetes, and the effect ot the drugs is only
indirect (Pastore et aL, 1984). We did not
observe typical diabetic symptoms and signs.
One ot our patients presented neurological
symptoms (contusion), and one had abdomen
and legs pain with coexistence ot sleepiness'
and mild increase ot thirst. Ali ot them had
hyperglicaemia (152 - 447 mg%), glucosuria
(1,5 - 8%) and ketonuria (+/++ - +/+++). Lack
ot gasometry abnormalities was tound to be
the same as in other reports (Pastore et aL,
1984; Skomra and Przybylska, 1992; Tatoń,
1985). The emphasis is put on normai insulin
level, despite the decrease ot synthesis during
leukemia, which distinguishes it trom "real"
diabetes (Pastore et aL, 1984; Tatoń, 1985). In
all our cases we applied a similar therapy, Le.
steroids and L-asparaginase cessation, diabetc
diet and insulin (Actrapid, Mixtard, Humulin R)
in doses based on current glucose serum
levels. Insulin therapy lasted 27, 10 and 5 days
respectively. In the tirst case, insulin
administration tor a longer period than
necessitated by glucose levels ("insulin cover")
made possible tinishing antileukemic therapy.
Other authors underline the possibility of
recuring to chemotherapy protocol after
diabetes regression, too. Ił covers as well
corticosteroid as L-asparaginase application,
even in cases with coexsisting serious
complications (Clavell et aL, 1986; Pastore et
aL, 1984; Skomra and Przybylska, 1992;). It
should be stressed, that establishing ot
diabetes is not described. The transitory
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character of glucose intolerance makes
possible to exclude disclosure ot typical
diabetes. In all our patients, abnormalities in
laboratory tests concerning Iiver funcfion were
detected, and in the first case - positive HGV
RNA - PGR test and increase of blood
pressure were tound. These changes may be
connected with leukemia duration. but may
also confirm, that diabetes is only one of many
different symptoms of toxicity connected with
modern antileukemic therapy.
CONCLUSIONS
Diabetes occuring during therapy of acute
Iymphoblastic leukemia has a complicated
etiology and differs in character from typical
diabetes.
The patients obtaining diabetogenic drugs,
Le. corticosteroids and L-asparaginase,
especialfy in combination, should be subject to
careful clinical observation and systematic
laboratory tests aimed at diagnosis ot diabetes.
Early diagnosis of diabetes and application of
right treatment permits early clinical and
biochemieal normalization, thereby continuation
of antileukemie therapy, even with diabetogenic
drugs application. -
Use ot insulin in the therapy ot diabetes
conneeted with leukemia may make reduce the
period ot hyperglycaemia and make
continuation ot ehemotherapy easier.
Diabetes in leukemie patients has a transitient
eharaeter and its establishing has not been
reported.
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